Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
18.64
-1.35 (-6.75%)
Mar 12, 2026, 2:53 PM EDT - Market open
Dyne Therapeutics Employees
Dyne Therapeutics had 258 employees as of December 31, 2025. The number of employees increased by 67 or 35.08% compared to the previous year.
Employees
258
Change
67
Growth
35.08%
Revenue / Employee
n/a
Profits / Employee
-$1,729,512
Market Cap
3.08B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 258 | 67 | 35.08% |
| Sep 30, 2025 | 240 | 67 | 38.73% |
| Jun 30, 2025 | 206 | 54 | 35.53% |
| Mar 31, 2025 | 192 | 49 | 34.27% |
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Sep 30, 2024 | 173 | 37 | 27.21% |
| Jun 30, 2024 | 152 | 18 | 13.43% |
| Mar 31, 2024 | 143 | 21 | 17.21% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Sep 30, 2023 | 136 | 21 | 18.26% |
| Jun 30, 2023 | 134 | 26 | 24.07% |
| Mar 31, 2023 | 122 | 26 | 27.08% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Sep 30, 2022 | 115 | 27 | 30.68% |
| Jun 30, 2022 | 108 | 37 | 52.11% |
| Mar 31, 2022 | 96 | 40 | 71.43% |
| Dec 31, 2021 | 93 | 46 | 97.87% |
| Sep 30, 2021 | 88 | 52 | 144.44% |
| Jun 30, 2021 | 71 | 34 | 91.89% |
| Mar 31, 2021 | 56 | 19 | 51.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Corcept Therapeutics | 730 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 249 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
DYN News
- 2 days ago - Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript - Seeking Alpha
- 3 days ago - Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case - Seeking Alpha
- 3 days ago - Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - GlobeNewsWire
- 3 days ago - Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 10 days ago - Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 15 days ago - Dyne Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - GlobeNewsWire
- 5 weeks ago - Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors - GlobeNewsWire